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Identity 
Other names: CD23; CD23A; CLEC4J; FCE2; IGEBF 




The gene is localized to the short arm of chromosome 
19. It contains 11 exons, and spans 13390 bps on minus 
strand. 
Transcription 
Normally expressed in B-cells. Its expression has been 
shown on T-cells, Langerhans cells, monocytes, 
macrophages, platelets, and eosinophils as well. 
Through alternative splicing 2 major isoforms are 
produced, FCER2a (CD23a) and FCER2b (CD23b), 
both of which are expressed on B-cells. FCER2a is 
constitutively expressed, whereas FCER2b is induced 
by several cytokines, especially by IL4. There are 3 
other splice forms, whose biological significance 





Essential role in the regulation of IgE production as 
well as differentiation of B cells. 
Description 
FCER2 is a Ca2+-dependent C-type lectin. The protein  
in humans contains 321 amino acids and has a 
molecular weight of 45 kDa. It has a single membrane-
spanning domain. The extracellular domain consists of 
an alpha-helical coiled coil domain, a lectin head, 
followed by a short tail region containing an inverse 
RGD sequence. The coiled coil domain and the lectin 
head section are critical for the formation of trimers, 
and IgE binding, respectively. The RGD sequence is a 
common recognition site of integrins. Through an 
autocatalytic process involving matrix 
metalloproteases, the membrane-bound FCER2 is 
turned into a series of soluble fragments (sFCER2) of 
molecular weight ranging between 17 and 37 kDa. The 
soluble forms are also biologically active. 
Expression 
FCER2 expression was first described in the thymic 
medullary B-lymphocytes, and subsequently, in a 
population of large thymic B-cells with dendritic 
features which were referred to as asteroid cells. 
FCER2 is mainly expressed on B cells. It is also 
expressed on T cells, Langerhans cells, monocytes, 
macrophages, platelets, and eosinophils. On B cells 2 
isoforms are present: a constitutively active form 
(FCER2a) and an inducible form (FCER2b). 
FCER2 expression is upregulated by its own ligand, i.e. 
IgE. Furthermore, upon treatment with IL4, increased 
FCER2 expression can be observed in several cell types 
including eosinophils, neutrophils, macrophages, 
monocytes, and T cells. In addition, EBV induces 
CD23 transcription through a regulatory element in 
intron 1 of FCER2a. 
FCER2 expression levels are differentially higher 
(70%) in mediastinal diffuse large B-cell lymphoma 
(med-DLBCL) and lower in nonmediastinal nodal 
DLBCL (15%) and extranodal DLBCL (9%). 






Atlas Genet Cytogenet Oncol Haematol. 2010; 14(10)  1006 
Localisation 
Although FCER2 expression is mainly localized to the 
surface of B-lymphocytes, it is widely distributed on 
the surface of various other cells including follicular 
dendritic cells (FDC), and even airway smooth muscle 
cells. 
Function 
FCER2 is the low-affinity immunoglobin E receptor. It 
mediates various biological functions. Mainly, it is 
involved in the down regulation of IgE production by B 
cells. However, because of its ability to associate with 
various ligands, its effects on IgE regulation might be 
stimulatory as well. In fact, FCER2 has been implicated 
in a variety of cellular functions ranging from cellular 
adhesion, antigen presentation, growth and 
differentiation of B and T cells, rescue from apoptosis, 
release of cytotoxic mediators, and regulation of IgE 
synthesis. 
FCER2 displays susceptibility to proteolytic cleavage 
which produces a soluble form of FCER2. As the 
soluble FCER2 does not have the ability to bind to the 
cell surface, this results in disruption of the feedback 
inhibition mechanism and increase of IgE production. 
As a result, soluble FCER2 has mitogenic properties. 
Furthermore, the proteolytic cleavage of FCER2 is 
probably the basis of various allergic reactions. 
These observations have been supported by cellular and 
animal models. Antibodies directed against the soluble 
FCER2 have been shown to inhibit the synthesis of 
IgE, while cross linking of membrane-bound FCER2 
inhibits B-cell growth and differentiation. Furthermore, 
FCER2-deficient mice produce higher levels of IgE, 
whereas mice overexpressing membrane-bound FCER2 
exhibit weaker IgE responses. 
Lumiliximab is an anti-CD23 antibody that is proposed 
in the therapy of chronic lymphocytic leukemia (CLL). 
Lumiliximab binds to cell surface membrane FCER, 
and induce apoptosis. Although previous reports 
indicated activation of the caspase cascade, the exact 
mechanism for apoptosis remains to be elucidated. 
Homology 
At this time a paralogous gene is not known in humans. 
It does not show similarity to FCER1, the other 
member of the immunoglobin E receptor family. 
Orthologues have been shown in mouse, rat and cow, 
with up to 58% homology at the protein level. 
However, some of the domains required for the proper 
function of human FCER2 is absent in orthologues. For 
example, the murine FCER2 does not have the RGD 
motif nor does it retain the IgE-binding affinity. 
Mutations 
Germinal 
An arginine to tryptophane substitution of amino acid 
62 (p.R62W) have been suggested to affect the receptor 
function and the mitogenic role of the protein. This 
suggestion was based on in vitro studies which showed 
the mutant protein was resistant to proteolytic cleavage 




Mediastinal diffuse large B-cell 
lymphoma (Med-DLBCL) 
Disease 
Med-DLBCL is a subtype of DLBCL that arise in the 
mediastinum from putative thymic B-cell origin. Its 
clinical, immunophenotypic, and genotypic features are 
distinctive. However, it has significant morphologic 
and immunophenotypic similarities with classical 
Hodgkin lymphoma (CHL) involving mediastinum. 
Since the prognosis and the first line of therapy for 
these conditions differ significantly, previous studies 
highlighted the usefulness of CD23 expression in the 
differential diagnosis of these conditions. Up to 85% of 
med-DLBCL patients are positive for FCER2, whereas 
only 10% of CHL patients show a weak FCER2 
staining, suggesting that FCER2 might be helpful to 
distinguish between med-DLBCL and CHL. 
Cytogenetics 
N/A 
Chronic lymphocytic leukemia (CLL) / 
small lymphocytic lymphoma (SLL) 
Disease 
CD23 positivity is noted in most cases of CLL/SLL and 
is used to differentiate CLL/SLL from mantle cell 
lymphoma that shares the CD5+ B-cell phenotype. The 
lack of CD23 in mantle cell lymphoma along with the 
dim expression of CD20 and light chain in CLL often 
help in this important distinction given the difference in 
prognosis and therapeutic options. However, some case 
of CLL/SLL may have an atypical phenotype including 




Nodal marginal zone B-cell lymphoma 
(NMZL) 
Disease 
NMZL is a rare form of non-Hodgkin lymphoma with 
primary presentation in the lymph node in the absence 
of clinical evidence of prior or concurrent involvement 
of extranodal sites or spleen. In a comprehensive study, 
FCER2 was found to highlight neoplastic cells in a case 
in which the staining was diffuse but weakly positive. 
Furthermore, the FCER2 staining highlighted residual 
and disrupted follicular dendritic cell (FDC) meshwork 
in 40% of the NMZL cases that were also highlighted 
by CD21 staining. 
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Cytogenetics 
N/A 
Follicular lymphoma (FL) 
Disease 
CD23 positivity by immunohistochemical analysis has 
been recently linked to a specific anatomic site in FL. 
Thorns et al. (2007) found that FLs in inguinal lymph 
nodes were more commonly CD23+ compared with FL 
from other anatomic sites. Katzenberger et al. (2009) 
demonstrated a high proportion of CD23+ cases in FLs 
with a diffuse growth pattern and a specific 
chromosomal alteration (deletion 1p36). CD23 
expression in FL was most recenlty reported to be 
associated with favorable outcome by Olteano et al. 
(2011) who also reported that CD23 positivity was 
more common in inguinal lymph nodes and in low-
grade cases. They postulated that CD23 expression is at 
least partially modulated by the tissue- and/or host-
specific factors (such as anatomic site or lower 
histologic grade) and suggested CD23 expression may 
be a surrogate for a certain host-specific (possibly, 
immune) environment that is associated with a more 
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